Monograph Details
|
|
Endocrine System
> Pituitary disorders
|
|
NUTROPIN AQ |
| Manufacturer |
|
Genentech, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Growth hormone (GH). |
| Generic Name |
|
Somatropin (rDNA origin) 5mg/mL; liq for SC inj; contains phenol. |
| Also |
|
• NUTROPIN
|
| Indications |
|
Growth failure in children due to inadequate GH secretion or associated with chronic renal insufficiency up to the time of renal transplant. Long-term treatment of short stature associated with Turner syndrome. Replacement therapy in select adults with adult GH deficiency. |
| Children |
|
Individualize. GH inadequacy: up to 0.043mg/kg SC daily; pubertal patients: up to 0.1mg/kg SC daily. Chronic renal insufficiency: up to 0.05mg/kg SC daily; dialysis: see literature. Turner syndrome: up to 0.375mg/kg per week SC divided into equal doses 3–7 times per week. |
| Adults |
|
Individualize. Initially not more than 0.006mg/kg SC daily, may increase to max 0.025mg/kg SC daily in adults <35yrs or 0.0125mg/kg SC daily in adults >35yrs. Elderly or obese: may need lower dose. |
| Contraindications |
|
Acute critical illness. Acute respiratory failure. Children with fused epiphyses. Neoplasia. Prader-Willi syndrome (severely obese or w. respiratory impairment): see literature. |
| Precautions |
|
Monitor gait, thyroid function, glucose tolerance, and for malignant transformation of skin lesions or for intracranial hypertension (do baseline and periodic funduscopic exams). Discontinue if signs of neoplasia of upper airway obstruction or sleep apnea occur. Not for use in patients with functioning renal allografts. History of intracranial lesions: monitor for lesion progression or recurrence. Scoliosis. Obtain baseline hip X-ray and monitor for renal osteodystrophy in renal failure. Monitor for otitis media, other ear disorders, and cardiovascular disorders in Turner syndrome. May elevate serum phosphate, alkaline phosphatase, parathyroid hormone. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May be antagonized by glucocorticoids. May affect CYP3A4 substrates. |
| Adverse Reactions |
|
Local reactions, intracranial hypertension, slipped capital epiphysis, antibody formation, edema, arthralgia, carpal tunnel syndrome, gynecomastia. |
| How Supplied |
Nutropin vial—2 (w. diluent)
Nutropin AQ (2mL) vial—1
Nutropin AQ (2mL) pen—1 |
|
|
|
|
